Patients On patient-centric treatment decisions and the value of quan... Marc Buyse, founder of IDDI and One2Treat, and also co-founder of CluePoints, discusses the pressing need for quantitative methodologies.
News Lilly's appeal unlocks EU approval of Alzheimer's drug Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy Kisunla has paid off.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face